Cours | Graphes | News | Analyses et conseils | Société | Historiques | Vie du titre | Secteur | Forum |
Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that it has published its first shareholder newsletter, highlighting the history of HIV/AIDS and ABIVAX’s HIV drug candidate, ABX464, which is in mid-stage clinical testing.
Currently available therapies are able to control the disease in most patients with HIV/AIDS, but there is still a large medical need for treatments that offer a functional cure or real cure. ABX464 may have the potential to provide a functional cure for HIV/AIDS because it does not appear to induce resistance and has a long-lasting effect. Formulated as a once-daily oral pill, ABX464 is easy to use. In testing to-date, its tolerability profile has been consistent with that of marketed HIV drugs.
Further information on ABIVAX, the history and current state of HIV/AIDS, and the innovative drug candidate ABX464 is available in the ABIVAX April 2016 newsletter, available by clicking here.
ABIVAX is an emerging global leader in the discovery, development
and commercialization of anti-viral therapeutics and therapeutic
vaccines to treat some of the world’s most life-threatening infectious
diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2
compounds in clinical stage research: ABX464 a novel first-in-class
resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a
therapeutic vaccine recently approved in Cuba and in late-stage clinical
development in other countries that could cure chronic Hepatitis B.
ABIVAX also is advancing additional anti-viral compounds and therapeutic
vaccines that may enter the clinical stage in the coming 18 months. A
recently updated corporate presentation, which includes a timeline for
the company’s anticipated news flow, is available at www.abivax.com.
Follow
us on Twitter @ABIVAX
View source version on businesswire.com: http://www.businesswire.com/news/home/20160509005987/en/
Vous avez aimé cet article ? Partagez-le avec vos amis avec les boutons ci-dessous.
02/04/24
Abivax : 261 millions de trésorerie, visibilité jusqu'à fin 2025
13/02/24
Abivax présentera ses résultats contre la RCH à Stockholm
13/02/24
Abivax: présentation sur obefazimod au congrès de l'ECCO
07/02/24
Abivax: nomination d'une responsable qualité
07/02/24
Abivax : Ana Sharma est nommée vice-présidente, global head of quality
Pour poster un commentaire, merci de vous identifier.